Intermediate Precision Lab Report

Procedure: I used a ruler, thermometer, and scale to take measurements. I used a graduated cylinder, short step pipet, scale, and ruler to determine volume and density. I used a volumetric flask, graduated pipet, pipet bulb, scale, and glass beaker to determine concentrations and densities of various dilutions.

The wet, crude product was placed into the 50 mL Erlenmeyer flask. Small amounts of CaCl2 were added to dry the solution. The flask was sealed and the mixture was swirled and left to settle. Once

Benzyltriphenylphosphonium chloride (0.201g) and 9-anthraldehyde (0.116g) were weighed and added to a short-neck round-bottomed flask (5ml). Dichloromethane (2ml) was measured using a measuring cylinder and added to the

Add 25 mL of distilled water into the beaker and stir with a glass rod to dissolve all the potassium iodate. Pour the potassium iodate solution through a filter funnel into a 250 mL volumetric flask. Rinse the beaker with distilled water and pour this water into the volumetric flask. Add in more distilled water to the volumetric flask up to the mark on the neck of the flask. Put the stopper in place and shake the flask until you get a homogenous solution. The standard solution is now ready for use in part B.

Then use a pipette and pipette filler to withdraw 10cm³of the solution and transfer it to a 100cm³conincal flask. Adding about 0.5g of solid potassium iodide to the conical flask ensuring to swirl the contents so that the solution turns brown due to the formation of iodide with a beige coloured precipitate of copper iodide.

In this experiment serial dilutions will be performed and from this, calibration curves will be produced. New solutions will be created from these dilutions and each new concentration will be found by using the concentration and volume formula

Mean values (n=3) of drug dissolution profiles are as shown in table 36. Standard deviation was not more than 2 in any case. It was observed that after storage of three months in stability chamber, drug release was decreased approximately by 5% while lag time was unaffected. Also for pellets stored at ambient conditions lag time was unaffected and drug release was lowered approximately by 5%.

Mean values (n=3) of drug dissolution profiles are as shown in table 36. Standard deviation was not more than 2 in any case. It was observed that after storage of three months in stability chamber, drug release was decreased approximately by 5% while lag time was unaffected. Also for pellets stored at ambient conditions lag time was unaffected and drug release was lowered approximately by 5%.

The accuracy parameter conducted by using the standard addition method. The proposed method afforded a recovery of 99.49-101.54% after the additional standard drug solution was spiked with the analyzed test solutions. The recovery percentages for Lamivudine, Zidovudine and Nevirapine were in the ranges from 99.80 to 101.06%, from

As the added drug would be diluted in the organ bath it was important to calculate doses with that in mind. Accordingly all calculations were made with the view of the end result, the final bath concentration (FBC). To achieve the correct final bath concentration it was assumed that the organ bath had a 25ml volume and then the corresponding quantity and concentration of drug was added. As an example, 0.25 ml of 10μmol/l concentration of drug X was added to ~24.75ml of Krebs’ solution to achieve a 1 in 100 dilution resulting in a final bath concentration of 0.1μmol/l.

Preoperatively, a client is to receive 75 mg of meperidine (Demerol) IM. The Demerol solution contains 50 mg/ml. How much solution should the nurse administer?

Stock solutions were prepared in isooctane, and then diluted into seven concentration levels, from 1 to 500 µg/L. The stock solution was kept at -18 °C until use.

Spray dried powder samples (5 mg) were weighed accurately and dissolved using a mixture of water/ methanol (80:20% v/v) in a 100 mL volumetric flask. The flasks were shaken at room temperature for 60 min on an orbital mixer incubator (Ratek Instruments Pty. Ltd., Victoria, Australia) at a speed of 200 rpm followed by bath sonication using an ultrasonic cleaner (Misonix Inc., NY, USA) for 15 min. The solutions were filtered, and the drug content of filtrates was quantified by HPLC analysis.

All chemicals, solvents and standards (purity > 98%) used in the study were commercially obtained from (Sigma-Aldrich, Germany) and were of analytical grade without further purification. The positive standards, including glibenclamide (purity ≥ 99%) and tramadol hydrochloride (purity ≥ 99%) were also obtained from Sigma-Aldrich, Germany. The purity of the tested compound 3 was ca. 95%, HPLC.

A storage facility of about 160,000 MT of concentrate (about 120,000 MT without contamination between the two concentrates)